What is it about?
Colorectal cancer (CRC) is one of the most common cancers in both gender; it is considered the third leading cause of death among other cancers. Despite new methods and drugs for the treatment of colorectal cancer and the good results obtained with them, there are a large number of chemicals and natural products that have not yet been studied and tested as anticancer agents. - The novel fluorine-boron hybrid complex L(BF2)2 is considered a new border derivative with notable anti-cancer potential.
Featured Image
Photo by julien Tromeur on Unsplash
Why is it important?
- For the first time, the apoptotic, cytotoxic and genotoxic properties of L(BF2)2 were investigated in colorectal cell lines at different concentrations. - The original study was performed using standard apoptotic and cytotoxic assays, such as single-cell gel electrophoresis assay (Comet assay), DNA fragmentation ladder, acridine orange assay for DNA damage, and ELISA to measure apoptosis.
Perspectives
Read the Original
This page is a summary of: Novel Fluorine Boron Hybrid Complex as Potential Antiproliferative Drugs on Colorectal Cancer Cell Line, Anti-Cancer Agents in Medicinal Chemistry, June 2019, Bentham Science Publishers,
DOI: 10.2174/1871520619666190117142353.
You can read the full text:
Contributors
The following have contributed to this page